All In MedTech

Device Trial Radar · NCT07940686

Evaluating Posterior Nasal Nerve Neurolysis for Migraine Relief

A Prospective Multicenter, Single Arm Pilot Study to Evaluate the Use of Posterior Nerve Neurolysis as a Treatment for Midfacial Migraine Headache (SOOTHE)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Mar 3, 2023

Primary completion

Nov 18, 2025

Study completion Jun 2, 2026

Sponsor

Lead sponsor
Aerin MedicalNot on our public-company list
Sponsor type
Industry
First posted
Nov 17, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of posterior nasal nerve (PNN) neurolysis on the migraine symptoms of patients diagnosed with midfacial migraine headaches, including the frequency and intensity of migraine headache episodes.

Conditions

  • Migraine Headache

Interventions

  • RhinAerDevice

    Low power radiofrequency energy delivery to the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Mid-facial Migraine Headache Days at 3 monthsTime frame: Baseline (pre-procedure) and 3 months post-procedure

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Alabama ENT & Allergy

    Birmingham, Alabama

  • Piedmont ENT

    Atlanta, Georgia

  • Madison ENT

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.